A small molecule inhibitor, arylidene-2-indolinone (RPI-1), abolishes the constitutive tyrosine phosphorylation caused by the specific RET proto-oncogene mutation seen at cysteine residue 634 in the syndrome multiple endocrine neoplasia type 2A (MEN2A). Here, RET is linked to multiple endocrine neoplasia type 2A.